The Pharmacy Compounding Advisory Committee narrowly voted to recommend adding six peptides to the official drug compounding list.

The Pharmacy Compounding Advisory Committee narrowly voted to recommend adding six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—to an approved list of ingredients for specialty pharmacies. This non-binding recommendation allows licensed pharmacies to create custom medications for patients with a doctor's prescription. The decision reflects a push to move popular compounds from the unregulated "gray market" into a regulated framework. While the committee members, many of whom run peptide clinics, argued that the move reduces harm by ensuring better quality control, FDA staff scientists remained skeptical. The agency's own reviewers unanimously opposed the additions, citing a lack of robust clinical trial data and potential risks of immune reactions. The administration announced support for the move through Robert F. Kennedy Jr., who oversees the FDA as the Health and Human Services Secretary. He views wider access to peptides as a way to reduce unnecessary barriers for patients. However, drug manufacturers warned that the move creates a loophole, as the list does not grant the same full safety and efficacy status as standard FDA-approved medications.

Sources